4-(3-(trifluoromethyl)phenylsulfonyl)piperidine | 849095-19-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(3-(trifluoromethyl)phenylsulfonyl)piperidine
• 英文别名: 4-[3-(Trifluoromethyl)phenyl]sulfonylpiperidine
• CAS: 849095-19-8
• 化学式: C₁₂H₁₄F₃NO₂S
• 分子量: 293.31
• InChiKey: UJWTUOAIOMKSOW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  54.6
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N-(2-chloroethyl)-2,2-dimethylpropanamide 、 4-(3-(trifluoromethyl)phenylsulfonyl)piperidine 在 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 168.0h， 生成 N-(2-(4-(3-(trifluoromethyl)phenylsulfonyl)piperidin-1-yl)ethyl)pivalamide
  参考文献：
  名称：

  [EN] ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS
  [FR] DÉRIVÉS D'ARYL SULFONES COMME BLOQUEURS DES CANAUX CALCIQUES

  摘要：

  揭示了在改善以不需要的钙通道活性为特征的情况下有效的方法和化合物，特别是不需要的N型和/或T型钙通道活性。具体来说，包含芳基磺酰基衍生物的一系列化合物被列举为示例，如公式（I）所示。

  公开号：

  WO2011035159A1

文献信息

• ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS
  申请人：Pajouhesh Hassan A.

  公开号：US20120245137A1

  公开（公告）日：2012-09-27

  Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type and/or T-type calcium channel activity, are disclosed. Specifically, a series of compounds containing aryl sulphone derivatives, as exemplified by Formula (I).

  本发明揭示了对于以不需要的钙通道活性，特别是不需要的N型和/或T型钙通道活性为特征的情况，有效改善的方法和化合物。具体地，本发明揭示了一系列含有芳基磺酰衍生物的化合物，例如公式（I）所示。
• ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS
  申请人：Yamagishi Tatsuya

  公开号：US20120232052A1

  公开（公告）日：2012-09-13

  The present invention relates to aryl carboxamide derivatives of formula (I), wherein Ar 1 is phenyl; Ar 2 is aryl; n is 1-4; X is —O—, —S—, —SO— or —SO 2 —, a prodrug thereof or a pharmaceutically acceptable salt thereof, which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of such disorders and diseases as pain in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases as pain in which voltage gated sodium channels are involved.

  本发明涉及公式（I）的芳基羧酰胺衍生物，其中Ar1是苯基；Ar2是芳基；n为1-4；X为—O—、—S—、—SO—或—SO2—，其前体药物或其药学上可接受的盐，具有阻断电压门控钠通道如TTX-S通道的活性，并在治疗或预防涉及电压门控钠通道的疾病和疾病，如疼痛方面中有用。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在预防或治疗涉及电压门控钠通道的疾病和疾病，如疼痛方面的使用。
• Discovery of benzothiazole-based adenosine A2B receptor antagonists with improved A2A selectivity
  作者：Fariborz Firooznia、Adrian Wai-Hing Cheung、John Brinkman、Joseph Grimsby、Mary Lou Gubler、Rachid Hamid、Nicholas Marcopulos、Gwendolyn Ramsey、Jenny Tan、Yang Wen、Ramakanth Sarabu

  DOI：10.1016/j.bmcl.2011.02.053

  日期：2011.4

  The highly potent but modestly selective N-(2-amino-4-methoxy-benzothiazol-7-yl)-N-ethyl-acetamide derivative 2 was selected as the starting point for the design of novel selective A(2B) antagonists, due to its excellent potency, and good drug-like properties. A series of compounds containing nonaromatic amides or ureas of five- or six-membered rings, and also bearing an m-trifluoromethyl-phenyl group (shown to impart superior potency) were prepared and evaluated for their selectivity against the A(2A) and A(1) receptors. This work resulted in the identification of compound 30, with excellent potency and high selectivity against both A(2A) and A(1) receptors. (C) 2011 Elsevier Ltd. All rights reserved.
• US9051296B2
  申请人：——

  公开号：US9051296B2

  公开（公告）日：2015-06-09
• [EN] ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS<br/>[FR] DÉRIVÉS D'ARYL SULFONES COMME BLOQUEURS DES CANAUX CALCIQUES
  申请人：ZALICUS PHARMACEUTICALS LTD

  公开号：WO2011035159A1

  公开（公告）日：2011-03-24

  Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type and/or T-type calcium channel activity, are disclosed. Specifically, a series of compounds containing aryl sulphone derivatives, as exemplified by Formula (I).

  揭示了在改善以不需要的钙通道活性为特征的情况下有效的方法和化合物，特别是不需要的N型和/或T型钙通道活性。具体来说，包含芳基磺酰基衍生物的一系列化合物被列举为示例，如公式（I）所示。